The young Danish biotech company Cobo Technologies will advise the FDA on clinical trials with the genome editing tool CRISPR. The company's proprietary product can potentially become the standard quality control of CRISPR-based treatments.
Log in to read our articles
Welcome to MedWatch. A part of our content is exclusive and reserved for our users.